Candel Therapeutics
CADL
21 hedge funds and large institutions have $9.7M invested in Candel Therapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2.29% less ownership
Funds ownership: 21.05% → 18.76% (-2.3%)
16% less funds holding
Funds holding: 25 → 21 (-4)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
49% less capital invested
Capital invested by funds: $19.1M → $9.7M (-$9.4M)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
E
Ergoteles
New York
|
+$51.7K |
| 2 |
Jane Street
New York
|
+$26.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.09K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.67K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$582 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$1.27M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$320K |
| 3 |
BlackRock
New York
|
-$170K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$53K |
| 5 |
Millennium Management
New York
|
-$47K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
BNP Paribas Financial Markets
Paris,
France
| – | -$1.29K | -410 | Closed |
|
|
CUAMC
27
China Universal Asset Management Company
Shanghai,
China
| – | -$1K | -271 | Closed |
|
CADL Hedge Fund Activity: Q4 2022 in Review
21 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Candel Therapeutics (CADL) for Q4 2022, worth a combined $9.7M — down 49% from $19.1M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CADL and 2 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 5 added.
The largest buyer was Ergoteles, opening a new position worth an estimated $51.7K. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.27M sold.
- 21 institutional investors held Candel Therapeutics (CADL) as of Q4 2022, down from 25 in Q3 2022.
- Funds reported $9.7M of Candel Therapeutics stock for Q4 2022, down 49% quarter-over-quarter.
- 2 funds opened new Candel Therapeutics positions in Q4 2022 and 6 closed out, a net change of -4 holders.
- The largest Candel Therapeutics buyer in Q4 2022 was Ergoteles, an estimated $51.7K added.
- The largest Candel Therapeutics seller in Q4 2022 was Point72 Asset Management, an estimated $1.27M sold.
Based on aggregated 13F filings for Q4 2022.